Stay updated on Dabrafenib/Trametinib in BRAF V600E+ Rare Cancers Clinical Trial
Sign up to get notified when there's something new on the Dabrafenib/Trametinib in BRAF V600E+ Rare Cancers Clinical Trial page.

Latest updates to the Dabrafenib/Trametinib in BRAF V600E+ Rare Cancers Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedCore content updated with a new diagnosis term and new revision, plus an operating-status notice; a prior cancer term and old version are removed.SummaryDifference1%
- Check21 days agoChange DetectedTerminology updated from 'Plasma cell myeloma' to 'Multiple myeloma' and version bumped from v3.0.2 to v3.1.0.SummaryDifference0.1%
- Check28 days agoNo Change Detected
- Check36 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2; the only other deletion is a minor UI element ('Back to Top') and does not affect core content.SummaryDifference0.1%
- Check43 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, names, pricing, or availability.SummaryDifference0.1%
- Check50 days agoChange DetectedThe web page has been updated to include new facility names and locations, as well as additional resources related to various cancers, while removing outdated location terms and some specific cancer resources. Notably, the names of drugs such as dabrafenib and trametinib have been added, indicating a focus on recent advancements in cancer treatment.SummaryDifference6%
- Check57 days agoChange DetectedThere are no significant changes to the web page content.SummaryDifference0.5%
Stay in the know with updates to Dabrafenib/Trametinib in BRAF V600E+ Rare Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dabrafenib/Trametinib in BRAF V600E+ Rare Cancers Clinical Trial page.